Trogenix unveils odyssey to find one-time tumor drugs with ‘unprecedented selectivity’.

Trogenix comes out of stealth, unveiling its innovative Synthetic Super-Enhancers (SSE) platform, Odysseus, to develop highly selective, one-time cancer treatments.

Equipped with £15 million ($19 million) in seed funding, Trogenix focuses on therapies targeting cancer cell states, enabling precision treatment of aggressive tumours while sparing healthy cells and activating long-term immune protection.